RxDoctor Payments Data

Aaryn McComb

Optometrist · Fort Worth, TXNPI 1205218104

Payments from drug & device makers

$1,597in general payments, 2019–2025

Across 64 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$541
  • Biotissue Holdings Inc.$185
  • Bausch & Lomb Americas Inc.$160
  • Novartis$144
  • AbbVie$128
  • Coopervision Inc.$103
  • plus $335 from 6 others

What the payments were for

  • Food & beverage$1,597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,597 in reported general payments places this provider in the 65th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$292,484
Medicare patients
740
Services billed
1,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine75$73,023
XiidraLifitegrast26$45,796
Cyclosporine29$24,872
MieboPerfluorohexyloctane/Pf26$21,921
TyrvayaVarenicline Tartrate13$8,214
Travoprost34$6,617
RocklatanNetarsudil Mesylat/Latanoprost12$4,281
Latanoprost284$3,447
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$3,413
Fluorometholone34$2,826
Loteprednol Etabonate15$1,715
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat78$1,672
Brimonidine Tartrate25$1,046
Prednisolone Acetate25$927
ErythromycinErythromycin Base55$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$128$73,02375 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$160$67,71752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →